Focus: OrganOx is a UK-based biotechnology company specializing in normothermic machine perfusion technology for organ transplantation, currently focused on liver transplant and acute liver failure indications. The company is publicly traded and operates as a niche player in the organ preservation and transplant technology space.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net -4 jobs in 30d
11 added, 15 removed. Backfill posture.
OrganOx presents a specialized growth opportunity for professionals seeking rare-disease/organ-tech expertise with public company stability, but limited clinical progress and financial opacity create execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for OrganOx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from OrganOx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles